Fentanyl: Nursing Drug Guide, Respiratory Depression & NCLEX Review
Healthcare medication guide: life-threatening respiratory depression prevention, 50 mcg/mL high-alert microgram dosing, continuous apnea monitoring, and naloxone-ready escalation for one of the most potent inpatient opioid analgesics.
Fentanyl citrate injection can cause serious, life-threatening, or fatal respiratory depression, especially during initiation or following a dose increase. The respiratory depressant effect may persist longer than the measured analgesic effect. The 50 mcg/mL concentration is a high-alert microgram product—mg versus mcg and decimal errors can be fatal. Highest-risk patients include those with COPD, sleep apnea, concurrent CNS depressants, and opioid-naive or debilitated patients. Nurses must use proper dosing and titration, continuous respiratory and sedation monitoring, ready access to naloxone, and immediate escalation for apnea or unarousable sedation.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every fentanyl dose—and for at least the interval recommended in your protocol afterward—assess respiratory rate, depth, oxygen saturation, and arousability. Respiratory depression can outlast analgesia; treat declining ventilation as an emergency even when pain scores improve.
Most common brand names
Fentanyl is available in multiple formulations across inpatient, procedural, and transdermal settings. This guide focuses on fentanyl citrate injection (equivalent to 50 mcg fentanyl base per mL). Always verify the specific product, concentration, and route on the MAR—not just the generic name.
Common injectable brands include Sublimaze and generic fentanyl citrate injection. Transdermal (Duragesic) and buccal/lozenge products are separate formulations with different absorption profiles and cannot be substituted for IV or IM citrate injection without prescriber and pharmacy review.
Why we give it — Indications
Fentanyl citrate injection is a potent opioid analgesic used when rapid, titratable pain control is needed and personnel trained in potent opioid respiratory management are available. It is substantially more potent than morphine on a microgram basis—dose verification is essential.
| Use | Detail |
|---|---|
| Analgesia and anesthesia adjunct | Indicated for analgesic action of short duration during anesthetic periods, premedication, induction, and maintenance, and in the immediate postoperative period (recovery room) when personnel trained in potent opioid respiratory management are immediately available per labeling. |
| Acute pain in monitored settings | Used when IV titration and continuous respiratory monitoring are feasible—typically perioperative, procedural sedation support, or critical-care environments with reversal agents accessible. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Fentanyl is a pure opioid agonist that binds mu-opioid receptors in the central nervous system, producing analgesia and dose-related respiratory depression. Onset is rapid after IV administration; the respiratory depressant effect may persist longer than the measured analgesic effect—a key nursing safety concept when titrating doses or transferring patients from recovery to the floor. Concurrent CNS depressants (benzodiazepines, other opioids, sedative-hypnotics) synergistically increase respiratory depression risk.
Dosing overview
Dosing must be individualized and titrated to effect under continuous monitoring. Fentanyl citrate injection is equivalent to 50 mcg fentanyl base per mL. Verify micrograms versus milligrams and independent double-check every dose against current prescribing information and local policy.
Missed dose: Not applicable to most PRN/titrated regimens. For scheduled perioperative doses, follow anesthesia or prescriber protocol; do not accumulate doses without reassessing respiratory status and cumulative opioid exposure.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (IV) | Rapid | Respiratory depression can follow quickly after bolus or dose increase—stay at bedside during titration when protocol requires |
| Duration of analgesia | Shorter than duration of respiratory depression per labeling | Do not assume safe ventilation because pain has returned; continue monitoring after analgesia wanes |
| Half-life | Context-dependent; redistribution affects early recovery | Repeat assessments during recovery; delayed depression may occur after transfer |
| Elimination | Hepatic metabolism; CYP3A4 substrate | CYP3A4 inhibitors (e.g., erythromycin) may increase fentanyl exposure—notify prescriber/pharmacist |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm trained personnel, continuous respiratory monitoring capability, and immediate access to opioid antagonist and resuscitation equipment per labeling
- Review baseline respiratory status, sleep apnea history, COPD, obesity hypoventilation, and concurrent CNS depressants (midazolam, diazepam, other opioids)
- Perform medication reconciliation for cumulative opioid and sedative exposure; verify microgram dose, mL volume (50 mcg/mL), and patient weight for pediatric orders
Contraindications
- Known hypersensitivity to fentanyl or fentanyl citrate injection excipients—this is the only contraindication listed in the reviewed fentanyl citrate injection prescribing information
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| CNS depressants (benzodiazepines, sedatives, other opioids) | Additive or synergistic respiratory depression and sedation | Reduce doses or avoid concurrent use when possible; increase monitoring frequency; hold and clarify if excessive sedation or bradypnea develops |
| CYP3A4 inhibitors (e.g., erythromycin, certain antifungals) | May increase fentanyl plasma concentration and prolong effect | Notify prescriber/pharmacist when new inhibitor started; monitor for increased sedation and respiratory depression |
| Mixed opioid agonist-antagonists (e.g., buprenorphine) | May reduce analgesia or precipitate withdrawal in dependent patients; respiratory effects unpredictable | Coordinate with prescriber/pharmacy before co-administration; monitor ventilation and withdrawal symptoms |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous or intramuscular fentanyl citrate injection (50 mcg/mL). Fentanyl is a Schedule II controlled substance—follow institutional controlled-substance and IV medication administration policies.
- Administer only by personnel trained in the use of potent opioids and in the recognition and management of respiratory depression per labeling
- Independent double-check microgram dose and mL volume; use smart pumps with dose limits when available
- Ensure opioid antagonist, airway equipment, and suction are immediately available during bolus or titration
- Document time, dose, route, indication, pre- and post-administration respiratory assessment, and who performed the double-check
At 50 mcg/mL, a 1 mL error can deliver a tenfold overdose relative to a intended 0.1 mL (5 mcg) miscalculation. Never interchange mg and mcg in orders or pump programming. Treat fentanyl citrate injection with the same rigor as other high-alert opioids.
Expected therapeutic response
- Decrease in pain score on standardized pain assessment without excessive sedation
- Respiratory rate and depth remain within prescriber or protocol parameters; patient remains easily arousable
- SpO2 stable on baseline oxygen therapy; no new bradypnea or shallow breathing pattern
Red flags — Stop and act
Respiratory depression may progress from subtle sedation to apnea within minutes after a bolus or dose increase. Escalate immediately—do not wait for pain reassessment alone.
- Respiratory rate below institutional threshold, shallow respirations, or absent respiratory effort (apnea)
- SpO2 decline, cyanosis, or new difficulty breathing despite supplemental oxygen
- Marked excessive sleepiness, inability to arouse patient, or confusion with somnolence
- Hypotension, bradycardia, or chest wall rigidity (rare but reported with rapid IV administration)
- Any suspicion of opioid overdose—initiate airway support and antagonist protocol per facility policy
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Respiratory depression | Serious; may be fatal | Stop opioid, support airway, administer antagonist per protocol, notify prescriber, continuous monitoring until spontaneous respiration reliably re-established |
| Sedation, dizziness, miosis | Common dose-related effects | Monitor sedation scale and respiratory rate; hold additional doses if oversedated |
| Nausea, vomiting | Common opioid effect | Supportive care; ensure airway protection if sedated |
| Hypotension, bradycardia | Reported with opioids | Monitor hemodynamics; correlate with volume status and concurrent anesthetics |
| Muscle rigidity (rapid IV) | Serious when reported | Notify anesthesia/prescriber immediately; may impair ventilation—support airway |
| Hypersensitivity | Uncommon | Discontinue permanently; treat per anaphylaxis protocol if severe |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose manifests primarily as respiratory depression, which may range from reduced respiratory rate to apnea. The respiratory depressant effect of fentanyl may outlast the analgesic effect; patients may appear comfortable while ventilation is inadequate.
Early signs
- Increasing sedation, small pupils, declining respiratory rate or depth
- Hypoxemia on pulse oximetry despite supplemental oxygen
Antidote
Opioid antagonists such as naloxone are specific antidotes to respiratory depression from opioid overdose per fentanyl citrate injection labeling. Titrate to restore adequate ventilation without precipitating acute withdrawal in physically dependent patients. Because the duration of opioid antagonist action may be shorter than fentanyl, continue monitoring and repeat doses per product labeling and protocol until spontaneous respiration is reliably re-established.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Maintain airway and ventilation while awaiting specialist input.
Look-alike / sound-alike and error prevention
- Fentanyl vs sufentanil vs remifentanil—verify generic name and concentration on vial and MAR; potency differs substantially
- mcg vs mg—most dangerous unit error with 50 mcg/mL injection; use leading zeros and avoid abbreviations
- Transdermal fentanyl vs injection—never substitute patch dosing for IV/IM microgram orders
- Fentanyl vs buprenorphine—different agonist-antagonist profile; verify correct product during reconciliation
- Decimal point errors—0.5 mL versus 0.05 mL at 50 mcg/mL equals 25 mcg versus 2.5 mcg; independent double-check mandatory
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Recovery handoff | Communicate total intraoperative/recovery opioid dose, last fentanyl time, baseline RR/SpO2, and whether antagonist was required before transfer. |
| Pump programming | Program in mcg with hard limits when available; confirm concentration 50 mcg/mL in smart pump library. |
| Monitoring interval | Follow institutional post-op opioid protocol—frequency increases after bolus or dose change. |
| Antagonist access | Verify naloxone location and dose before giving fentanyl in procedural or recovery areas. |
| Commonly missed | Concurrent PRN benzodiazepine orders and residual anesthesia sedatives still active when recovery fentanyl is ordered. |
| Ask pharmacy when | CYP3A4 inhibitor added, unclear mcg/mL calculation, or partial antagonist response with recurrent depression. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Opioid-naive, elderly, debilitated | Increased sensitivity to respiratory depression; use lowest effective microgram dose and extended monitoring per labeling warnings. |
| Chronic pulmonary disease / sleep apnea | Decreased respiratory reserve; even therapeutic doses may cause hypoxemia—lower starting doses and continuous SpO2 monitoring. |
| Concurrent CNS depressants | Benzodiazepines and other sedatives markedly increase fatal respiratory depression risk—coordinate dose reduction with prescriber. |
| Pediatrics (2–12 years) | Initiate 2–3 mcg/kg; weight-based math errors are high risk; recovery personnel must remain immediately available per labeling. |
| Physical opioid dependence | Antagonist titration must balance reversal of respiratory depression against precipitated withdrawal; consult prescriber for repeated antagonist needs. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory rate, depth, and pattern; sedation level; blood pressure and heart rate per protocol
- Continuous or frequent pulse oximetry during titration and early recovery; capnography when available
- Pain scores alongside ventilation—analgesia without adequate respiration is not a safe outcome
Document
- Dose (mcg and mL), route, time, indication, pre/post respiratory assessment, and independent double-check
- Cumulative opioid and sedative exposure at handoff; antagonist doses and patient response if given
- Patient education on reporting somnolence, breathing difficulty, and when to seek urgent help
Patient teaching
- Fentanyl can slow breathing to a dangerous level—report unusual sleepiness, slow or shallow breathing, or difficulty staying awake
- Do not take other sedatives, alcohol, or extra pain medicine unless the prescriber approves—combined drugs increase overdose risk
- A family member or caregiver should know how to recognize opioid overdose and how your facility instructs them to seek urgent help
- Seek emergency care for severe breathing difficulty or inability to arouse; contact local poison control or toxicology services per facility protocol for overdose guidance
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to fentanyl (only labeled contraindication)
- Respiratory rate or SpO2 below prescriber or protocol threshold; apnea; or patient unarousable
- Unclear microgram versus milligram order, wrong concentration selected, or independent double-check mismatch
- New concurrent CNS depressant without a revised safe opioid plan
- Personnel trained in potent opioid respiratory management or antagonist equipment not immediately available per labeling requirements
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Fentanyl citrate injection is a Schedule II high-alert opioid whose primary nursing failure mode is unrecognized respiratory depression after the team focuses on pain scores. Build ventilation checks into every opioid pass, especially during recovery handoffs when benzodiazepines and inhalational anesthetics may still be active.
1. Check-before-you-give protocol
- Right patient, right drug, right microgram dose, right mL (50 mcg/mL), right route, right time—and right cumulative opioid total
- Independent double-check with second licensed clinician for bolus and infusion starts
- Confirm antagonist, airway equipment, and trained responder immediately available
- Baseline RR, SpO2, and sedation score documented before dose and per protocol after
2. High-alert and safety badge
Schedule II high-alert opioid — 50 mcg/mL concentrationFentanyl citrate injection labeling requires administration only by personnel trained in potent opioid use and respiratory depression management, with opioid antagonist and resuscitation equipment available.
3. Clinical workflow: hold and question rules
- If RR is declining or SpO2 falling after a dose, hold further opioid and escalate before repeating analgesia
- Recovery handoff must include last fentanyl dose, concurrent sedatives, and whether ventilation is stable—not pain score alone
- Contact poison control or toxicology per facility protocol when overdose is suspected; maintain airway while awaiting guidance
4. Critical teach-back questions
- “What breathing changes should you report right away while receiving fentanyl?” (Patient should name slow or shallow breathing, extreme sleepiness, or difficulty waking up.)
- “Why might nurses wake you to check breathing even when your pain is well controlled?” (Patient should understand respiratory depression can outlast pain relief and needs monitoring.)
5. Care coordination
Pharmacist: Consult for CYP3A4 interaction review, mcg/mL verification, and antagonist dosing when partial or recurrent reversal occurs
Prescriber / anesthesia: Notify for persistent respiratory depression, need for alternate analgesia, or repeated naloxone doses
🧠 Quick mental checklist
- What is this patient’s respiratory rate, depth, SpO2, and arousability right now?
- What fentanyl and other opioids/sedatives have they received in the last 24 hours?
- Is the order in micrograms with the correct mL for 50 mcg/mL?
- Are antagonist and airway support immediately available?
- If ventilation is declining, have I stopped the opioid and activated escalation?
Fentanyl NCLEX practice questions
Practice NCLEX-style clinical judgment practice for fentanyl citrate injection using a tabbed postoperative case (MAR, labs, vitals, nursing notes), then rotate priority action, respiratory cue recognition, deterioration trends, matrix urgency sorting, antagonist management, and antidote cloze—recognise cues → analyse → prioritise → act → evaluate outcomes tied to respiratory depression risk.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Fentanyl citrate injection 50 mcg IV once at 1430 for post-op pain (50 mcg/mL — 1 mL)
- Midazolam 1 mg IV at 1415 documented in anesthesia record
- Morphine PCA not yet ordered; fentanyl 25 mcg IV PRN q15min — maximum 3 doses/ hour
- 1515: patient reports pain 6/10; no additional fentanyl documented yet
- Admission BMP: within reference range; no acute metabolic acidosis
- ABG not drawn; pulse oximetry primary oxygen monitoring in recovery
- Pharmacy note: new erythromycin order for post-op infection prophylaxis — CYP3A4 inhibitor interaction review pending
- 1430 (post 50 mcg fentanyl): RR 14, SpO2 96% on room air, BP 118/72, arousable
- 1500: RR 10, SpO2 93% on 2 L/min nasal cannula, mild somnolence
- 1515: RR 8, SpO2 90% on 2 L/min, difficult to arouse with verbal stimulus
- History: 62-year-old with COPD; laparoscopic colectomy; day 0 recovery
- 1510: Patient drifting to sleep between questions; denies chest pain
- 1515: Nurse reviewing vitals tab before giving PRN fentanyl 25 mcg for pain 6/10
- Naloxone and airway cart verified at bedside per recovery policy
Answer key & rationale
Frequently asked questions
What is the greatest nursing safety risk with fentanyl citrate injection?
Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or after a dose increase. The respiratory depressant effect may persist longer than the measured analgesic effect. Nurses must use proper dosing and titration, continuous respiratory monitoring, and ready access to an opioid antagonist per labeling.
What starting dose does prescribing information give for adults and children?
For adults, initiate treatment with 50 mcg to 100 mcg. For children 2 to 12 years of age, initiate with a reduced dose as low as 2 mcg/kg to 3 mcg/kg. Fentanyl citrate injection is equivalent to 50 mcg fentanyl base per mL and may be given IV or IM.
How should a nurse respond to suspected fentanyl respiratory depression?
Stop further opioid, support the airway, administer an opioid antagonist such as naloxone per facility protocol, notify the prescriber, and monitor continuously because antagonist duration may be shorter than fentanyl action. Contact local poison control or medical toxicology services for overdose guidance per facility protocol.
What is the only contraindication listed for fentanyl citrate injection?
Known hypersensitivity to fentanyl or the formulation excipients. All other risks (respiratory disease, CNS depressants, debilitation) require caution, dose adjustment, and monitoring—not absolute contraindication in the reviewed labeling.
Why is fentanyl citrate injection a Schedule II high-alert medication?
Fentanyl is a Schedule II controlled substance with high misuse and overdose potential. The 50 mcg/mL concentration makes decimal and unit errors dangerous. Labeling requires administration only by personnel trained in potent opioid respiratory management with antagonist and resuscitation equipment available.
When should a nurse hold fentanyl and contact the prescriber or pharmacist?
Hold for hypersensitivity, inadequate ventilation (apnea, excessive sedation, declining SpO2), unclear mcg versus mg orders, unavailable trained personnel or antagonist per labeling, or new CYP3A4 inhibitors such as erythromycin without dosage review.
References
-
U.S. National Library of Medicine. Fentanyl citrate injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38d0c14a-a0c1-44cc-a939-0304eb8037d6
-
U.S. Food and Drug Administration. Fentanyl citrate injection (ANDA 016619) — Prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016619s054lbl.pdf
-
U.S. Drug Enforcement Administration. Drug Scheduling.https://www.dea.gov/drug-information/drug-scheduling
-
Institute for Safe Medication Practices. High-alert medications in acute care settings.https://www.ismp.org/recommendations/high-alert-medications-acute-list
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks from combined use.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-strong-warnings-opioid-analgesics-prescription-opioid
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.